All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2018; the latest 2020-07-06.
From the record
Avita Medical, Inc.'s filings since 2018 show 1 warning event: an auditor change (8-K item 4.01, the latest 2020-07-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+78.4% a year over 8 filed years; profitable in 0 of 8.
From the record
Avita Medical, Inc.'s 8 filed years say what it did: revenue went from $929 thousand in fiscal 2018 to $72 million in fiscal 2025, up 78.4% a year; it rose in 7 of 7 years; it never fell from a peak; net income was positive in 0 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Avita Medical, Inc.'s shareholder treatment is put at 6.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 40% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 130%: owes 130¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Avita Medical, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 104 cents per dollar of everything the company owns. Leverage: it owed about 130 cents per dollar of assets, and net share issuance: its share count grew 7.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 50% of 109 in its family; net margin -67.8%.
From the record
Avita Medical, Inc.'s standing among 109 graded names in its industry family: revenue of $72 million in fiscal 2025 ranks in the bottom 46% by size; a net margin of -67.8% ranks in the bottom 29%; revenue growth of 27.7% a year over the last 3 filed years ranks in the top 26% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 18% of 91 in its family for leadership; chief executive since 2026.
From the record
Avita Medical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Vance, Cary Guy (President and CEO, as filed), filing under that title since 2026-06-01, 5 months (bottom 11% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 3.6 years (bottom 19%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 38% of 104 in its family for room to expand.
From the record
Avita Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $10 million against debt of $0 thousand leaves 18.2% of its assets as net cash, top 38% of its family; cash from operations less capital spending is -45% of revenue (bottom 31%); a gross margin of 82.1% (top 12%); research spending of 29.1% of revenue (top 31%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 50% of 105 in its family for growth drivers.
From the record
Avita Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 27.7% a year over the last three filed years against 78.4% over all 8, slowing (bottom 3% of its family); the newest year grew 11.5% (bottom 44%); research spending grew 14.6% a year (top 28%); capital spending grew 30.5% a year (top 16%) (its annual reports). Avita Medical, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 38% of 88 in its family for expectations against reality.
From the record
Avita Medical, Inc.'s newest year against its own record: revenue of $72 million in fiscal 2025 came in 18.4% below the $88 million its prior three years' pace pointed to (bottom 24% of its family); net income of $49 million against a prior three-year average of $41 million (bottom 31%); a net margin of -67.8% against -81.4% before (top 43%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made